Which of the following statements comparing serotonin-dopamine antagonists (SDAs) with dopamine receptor antagonists (DRAs) is true?
Ans. D. SDAs affect both serotonin and glutamate receptorsThe serotonin-dopamine antagonists (SDAs) affect both serotonin and glutamate receptors. However, the SDAs produce minimal or no extrapyramidal symptoms and interact with different subtypes of dopamine receptors than do the standard antipsychotics. They also produce fewer neurological adverse effects and are effective in treating negative symptoms of schizophrenia. They are at least as effective as haloperidol for positive symptoms and are uniquely effective for the negative symptoms. These drugs have replaced the dopamine receptor antagonists as the drug of first choice for the treatment of schizophrenia.
DRAs is first choice of treatment for schizophrenia.
SDAs produce more neurological adverse effects.
SDAs produce more extrapyramidal symptoms.
SDAs affect both serotonin and glutamate receptors.
Pharmacotherapy In Psychiatry